

1

2 *CASC3 promotes transcriptome-wide activation of nonsense-  
3 mediated decay by the exon junction complex*

4

5 **Jennifer V. Gerbracht<sup>1</sup>, Volker Boehm<sup>1</sup>, Thiago Britto-Borges<sup>2,3</sup>, Sebastian Kallabis<sup>4</sup>, Janica L.  
6 Wiederstein<sup>4</sup>, Simona Ciriello<sup>1,5</sup>, Dominik U. Aschemeier<sup>1</sup>, Marcus Krüger<sup>4</sup>, Christian K.  
7 Frese<sup>4,6</sup>, Janine Altmüller<sup>7,8</sup>, Christoph Dieterich<sup>2,3</sup>, Niels H. Gehring<sup>1</sup>**

8 <sup>1</sup> Institute for Genetics, University of Cologne, 50674 Cologne, Germany

9 <sup>2</sup> Section of Bioinformatics and Systems Cardiology, Department of Internal Medicine III and Klaus  
10 Tschira Institute for Integrative Computational Cardiology, University of Heidelberg, 69120 Heidelberg,  
11 Germany

12 <sup>3</sup> DZHK (German Centre for Cardiovascular Research), Partner site Heidelberg/Mannheim, 69120  
13 Heidelberg, Germany

14 <sup>4</sup> CECAD Research Center, University of Cologne, Joseph-Stelzmann-Str. 26, 50931 Cologne, Germany

15 <sup>5</sup> present address: AO Research Institute Davos, Clavadelerstrasse 8, CH-7270 Davos Platz, Switzerland

16 <sup>6</sup> present address: Max Planck Unit for the Science of Pathogens, 10117 Berlin, Germany

17 <sup>7</sup> Cologne Center for Genomics (CCG), University of Cologne, 50931 Cologne, Germany

18 <sup>8</sup> Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany

19

20

21 **Contact**

22 Niels H. Gehring, University of Cologne, Institute for Genetics, Zuelpicher Str. 47a, 50674 Cologne,  
23 Germany; email: ngehring@uni-koeln.de

24

25

26

27 **Running Title (40 Characters)**

28 CASC3 promotes EJC-dependent NMD

29 **Keywords (5, alphabetical order, separated by slash)**

30 CRISPR-Cas9/gene expression/mRNA quality control/NMD/RNA degradation

31

32 **Abstract**

33 The exon junction complex (EJC) is an essential constituent and regulator of spliced messenger  
34 ribonucleoprotein particles (mRNPs) in metazoans. As a core component of the EJC, CASC3 was  
35 described to be pivotal for EJC-dependent nuclear and cytoplasmic processes. However, recent  
36 evidence suggests that CASC3 functions differently from other EJC core proteins. Here, we have  
37 established human CASC3 knockout cell lines to elucidate the cellular role of CASC3. In the knockout  
38 cells, overall EJC composition and EJC-dependent splicing are unchanged, whereas mRNA isoforms  
39 targeted by nonsense-mediated decay (NMD) are upregulated on a transcriptome-wide scale.  
40 Mechanistically, recruiting CASC3 to reporter mRNAs by direct tethering or via binding to the EJC  
41 stimulates mRNA decay and endonucleolytic cleavage at the termination codon. Building on existing  
42 EJC-NMD models, we propose that CASC3 equips the EJC with the ability to communicate with the  
43 NMD machinery in the cytoplasm. Collectively, our results characterize CASC3 as a peripheral EJC  
44 protein that tailors the transcriptome by promoting the degradation of EJC-dependent NMD  
45 substrates.

46

47 **Introduction**

48 Messenger RNA-binding proteins (mRBPs) determine the stability, location, and fate of bound  
49 mRNAs and are therefore important regulators of post-transcriptional gene expression (Hentze *et al.*,  
50 2018). A central component of spliced mRNPs in metazoans is the exon-junction-complex (EJC), which  
51 is deposited during splicing upstream of exon-exon boundaries (Boehm & Gehring, 2016, Le Hir *et al.*,  
52 2016, Woodward *et al.*, 2017). The heterotetrameric core of the EJC is composed of the proteins  
53 EIF4A3, MAGOH, RBM8A (Y14) and CASC3 (BTZ, MLN51) (Andersen *et al.*, 2006, Bono *et al.*, 2006).  
54 Generally, EJCs serve on spliced mRNAs as a mark that act as a binding platform for peripheral EJC-  
55 interacting factors (Singh *et al.*, 2012). The core and peripheral EJC components contribute to different  
56 steps of post-transcriptional gene expression including splicing regulation, mRNA localization,  
57 translation and nonsense-mediated mRNA decay (NMD) (Boehm & Gehring, 2016, Woodward *et al.*,  
58 2017).

59 The EJC does not form spontaneously, but instead undergoes stepwise assembly in association  
60 with the spliceosome, while it proceeds through different spliceosomal complexes (Gerbracht &  
61 Gehring, 2018). As a first step, the splicing factor CWC22 recruits EIF4A3, to which the MAGOH/RBM8A  
62 heterodimer binds later on (Gehring *et al.*, 2009, Alexandrov *et al.*, 2012, Barbosa *et al.*, 2012,  
63 Steckelberg *et al.*, 2012, Steckelberg *et al.*, 2015). Unlike the three spliceosome-associated EJC  
64 components EIF4A3, MAGOH and RBM8A, the fourth protein CASC3 is absent from the purified  
65 spliceosomal C complex (Bessonov *et al.*, 2008). Furthermore, it cannot be detected in mRNPs formed  
66 on splicing intermediates (Gehring *et al.*, 2009). Therefore, it was suggested that CASC3 binds to the  
67 initially formed trimeric pre-EJC (consisting of EIF4A3, MAGOH and RBM8A) at a later stage.  
68 Interestingly, CASC3 has also been shown to be a shuttling protein that is mainly located in the  
69 cytoplasm, whereas the other EJC components are predominantly detected in the nucleus (Kataoka *et*  
70 *al.*, 2000, Le Hir *et al.*, 2001, Degot *et al.*, 2002, Palacios *et al.*, 2004, Shibuya *et al.*, 2004). It has  
71 therefore been suggested that CASC3 binds to the EJC in the nucleus and is transported with it into the  
72 cytoplasm (Ballut *et al.*, 2005). A recent study demonstrated that EJCs undergo a compositional switch

73 and that the ASAP/PSAP component RNPS1 and the protein CASC3 bind to functionally different  
74 mRNPs and exist in mutually exclusive EJCs (Mabin *et al.*, 2018). While EJCs of nuclear enriched  
75 transcripts were found to interact with RNPS1, the EJCs of cytoplasmic enriched transcripts rather  
76 contained CASC3. This observation is in line with the predominantly cytoplasmic localization of CASC3,  
77 but would argue against a nuclear function.

78 Another aspect under debate is the involvement of CASC3 in the NMD pathway. According to the  
79 EJC-dependent model of NMD, an EJC present more than 50-55 nucleotides downstream of a  
80 premature termination codon (PTC) triggers degradation by the NMD machinery (Nagy & Maquat,  
81 1998). This quality control mechanism rids the cells from aberrant transcripts that contain PTCs due to  
82 mutations or mis-splicing. Additionally, it serves as a post-transcriptional mechanism of gene  
83 expression, especially when coupled to alternative splicing (Nasif *et al.*, 2018). This is a common  
84 feature of many genes coding for mRBPs, e.g. most SR proteins (Lareau *et al.*, 2007, Ni *et al.*, 2007).  
85 The EJC triggers NMD by interacting with members of the SURF complex resulting in phosphorylation  
86 of the central NMD factor UPF1 (Kashima *et al.*, 2006). Phosphorylated UPF1 then stimulates two  
87 distinct degradation pathways of NMD: The SMG5/7-dependent pathway results in deadenylation and  
88 decapping of the transcript followed by exonucleolytic decay from the 5' end by XRN1 and the 3' end  
89 by the exosome (Loh *et al.*, 2013). Alternatively, the transcript can be cleaved in the vicinity of the PTC  
90 by the endonuclease SMG6 which results in two mRNA fragments that can be exonucleolytically  
91 degraded by XRN1 and the exosome (Huntzinger *et al.*, 2008, Eberle *et al.*, 2009). While these pathways  
92 can act redundantly and in principle compensate for each other, SMG6-dependent endonucleolytic  
93 cleavage (endocleavage) has been shown to be the dominant pathways for NMD in human cells  
94 (Boehm *et al.*, 2014, Lykke-Andersen *et al.*, 2014, Colombo *et al.*, 2017). In cells depleted of CASC3 a  
95 stabilizing effect on PTC-containing reporter mRNAs and selected endogenous targets was reported  
96 (Palacios *et al.*, 2004, Gehring *et al.*, 2005, Gehring *et al.*, 2009). Furthermore, tethering CASC3 to an  
97 mRNA results in UPF1-dependent degradation of the transcript (Gehring *et al.*, 2009). However, a

98 recent report has challenged these observations and showed that CASC3 plays a minor role in NMD  
99 and only for certain endogenous targets in contrast to EIF4A3 or RNPS1 (Mabin *et al.*, 2018).

100 We were intrigued by the contrasting reports about the enigmatic role of CASC3 and decided to  
101 investigate the function of CASC3 and its distinction to the other EJC core components in more detail.  
102 For this purpose, we established HEK 293 CASC3 knockout (KO) cells using CRISPR-Cas9-mediated gene  
103 editing. The CASC3 KO cell lines are unchanged in their composition of the EJC core and peripheral  
104 interacting proteins. However, RNA-sequencing reveals an upregulation of transcript variants  
105 containing premature-termination codons (PTC) as well as the differential expression of many known  
106 NMD targets, indicating a perturbation of this decay pathway. Mechanistically, CASC3 stimulates  
107 SMG6-dependent turnover of NMD targets and likely acts as a link from the EJC to the NMD machinery.  
108 On the basis of these results we propose a revised model of EJC-dependent NMD in human cells.

109 **Results**

110 ***CASC3 is dispensable for nuclear EJC functions***

111 Previously, we and others have shown that depletion of EJC core components in human  
112 cells leads to pervasive re-splicing of cryptic splice sites, resulting in aberrant splice variants lacking  
113 exonic sequences (schematically depicted in Supplementary Figure 1) (Wang *et al.*, 2014, Boehm  
114 *et al.*, 2018). Mechanistically, the EJC prevents the use of cryptic splice sites either by interaction  
115 with the ASAP/PSAP component RNPS1 or by sterically masking splice sites (Boehm *et al.*, 2018).  
116 In keeping with previous observations from HeLa cells, the knockdowns of the EJC core  
117 components EIF4A3 or RBM8A in HEK293 cells resulted in exon-skipping of the mRNAs for RER1,  
118 OCIAD1 and MRPL3 (Figure 1 A-C). Surprisingly, a knockdown of the EJC core factor CASC3 did not  
119 result in mis-splicing of these three selected transcripts. (Figure 1A-C). However, the knockdown  
120 of CASC3 increased the abundance of an alternative transcript isoform of the SR protein SRSF2,  
121 which is known to be targeted by NMD (Figure 1D) (Sureau *et al.*, 2001, Wollerton *et al.*, 2004).  
122 Together, these results indicate that CASC3 contributes to NMD activation by the EJC, but is not  
123 required for EJC-dependent splicing regulation. Given that the generation of EJC-specific splice  
124 isoforms is a readout for EJC assembly, the initial formation of EJCs does not seem to be affected  
125 by the knockdown of CASC3.

126 ***EJC assembly is unaffected in CASC3 knockout cells***

127 Although the knockdown efficiency of CASC3 was substantial (Figure 1E), we wished to  
128 exclude that residual amounts of CASC3 prevented a reliable assessment of the protein's function.  
129 Since CASC3 was found to be non-essential in multiple genome-wide screens of human  
130 immortalized cell lines, we reasoned that knockout (KO) of CASC3 should be feasible (Hart *et al.*,  
131 2015, Hart *et al.*, 2017). Accordingly, we obtained three cell lines by CRISPR-Cas9-mediated gene  
132 editing, designated H, F, and T lacking the CASC3-specific 130 kDa band on a western blot (Figure  
133 2A). In all cell lines we detected genomic insertions of different length and sequence at the

134 beginning of the coding region of CASC3, which resulted in frame shifts of the downstream coding  
135 region or, in the case of cell line T, contained in-frame termination codons (Figure 2B,  
136 Supplemental Figure 2A and B). For the cell lines H and F, we observed an additional band of 100  
137 kDa on western blots with antibodies recognizing the C-terminal or central region of CASC3 (Figure  
138 2A, red arrow, Supplementary Figure 2A and C). This cross-reactive protein interacted with FLAG-  
139 tagged EIF4A3 and disappeared upon treatment with siRNAs against CASC3 (Figure 2C,  
140 Supplementary Figure 2C and D). This suggests that the cell lines H and F produce an N-terminally  
141 truncated form of CASC3, presumably representing a novel, non-canonical protein product. Such  
142 aberrant proteins have been recently described in a systematic analysis to be common by-products  
143 of CRISPR-Cas9 genome editing (Tuladhar *et al.*, 2019).

144 To assess the composition of exon junction complexes and their peripheral interacting  
145 proteins in the absence of CASC3 KO, we analyzed the FLAG-tagged EIF4A3 interactome in the cell  
146 line H and wild type cells using mass spectrometry. EIF4A3 was successfully enriched, together  
147 with other known EJC complex members (Supplemental Figure 2E). Although co-precipitated  
148 CASC3 was strongly reduced in the knockout cell line (Supplemental Figure 2G, log2 fold change =  
149 -3.75), it was enriched relative to the control (Supplemental Figure 2F, log2 fold change = 2.43).  
150 This confirmed that residual amounts of CASC3 protein are still present in the knockout cell line H.  
151 When the cells were treated additionally with CASC3 siRNAs, the amount of CASC3 pulled down  
152 by EIF4A3 was reduced to background levels (Figure 2D and E). Therefore, the cell lines H and F are  
153 comparable to a constitutive knockdown of CASC3, whereas the cell line T (without further  
154 treatment) and cell line H in combination with CASC3 siRNA treatment completely lack detectable  
155 CASC3 protein. This set of cell lines enables a hitherto unfeasible analysis of CASC3's cellular  
156 function as part of the EJC.

157

158 Strikingly, no other EJC core factor or splicing regulatory EJC component (e.g. ASAP/PSAP) was  
159 significantly altered in the CASC3-depleted condition (Figure 2F). This is in line with our initial  
160 conclusion that splicing-regulatory EJCs can assembly even in the absence of CASC3. Further  
161 support comes from co-immunoprecipitation analysis of EIF4A3, which demonstrated unchanged  
162 interaction with the EJC component MAGOH in the CASC3 knockout cell line H (Supplementary  
163 Figure 2H). In agreement with the data obtained from the knockdown of CASC3 in Figure 1,  
164 transcripts containing EJC-dependent splice sites were correctly spliced in CASC3 KO cells (Figure  
165 2G and H, Supplementary Figure 2I and J), indicating that CASC3 is not necessary for correct and  
166 stable deposition of the EJC during splicing and its subsequent nuclear splice function. The role of  
167 CASC3 during EJC assembly was also characterized by performing *in vitro* splicing of a MINX intron  
168 in cell lysates obtained from the cell line H (Figure 2I and Supplementary Figure 2K). Notably, the  
169 overall splicing efficiency of the MINX transcript was slightly reduced in the input of CASC3 KO  
170 lysates when compared to wild-type lysates. However, spliced RNA was pulled down to the same  
171 extent by EIF4A3 (2.97% in KO vs. 3.01% in WT), suggesting that EIF4A3 is deposited on spliced  
172 mRNA even when CASC3 is strongly depleted. In the absence of CASC3, the only other protein that  
173 was significantly, although mildly reduced in EIF4A3-IPs was the NMD factor UPF3B (Figure 2F, log2  
174 fold change = -1.52). UPF3B links the EJC to the NMD machinery via direct interactions (Buchwald  
175 *et al.*, 2010) and was recently found to be enriched in cytoplasmic CASC3-loaded EJCs (Mabin *et*  
176 *al.*, 2018). The reduction of NMD-competent EJCs could contribute to the NMD impairment that  
177 we observed upon loss of CASC3.

### 178 **CASC3 regulates NMD-sensitive isoforms**

179 To investigate the global effects of CASC3 depletion on the transcriptome, we performed RNA-  
180 sequencing (RNA-seq) of the cell lines H and T either treated with CASC3 or control siRNAs (Figure  
181 3A) and identified differentially expressed genes (Supplementary Figure 3A and 3B, Supplementary  
182 Table 4). To exclude clone-specific and siRNA treatment-related effects, we compared the  
183 identified targets between the four conditions. Overall, the high number and the substantial

184 overlap of upregulated genes suggests that CASC3 KO mainly results in the accumulation of certain  
185 transcripts (Figure 3B and C, Supplementary Figure 3C). This observation fits with the hypothesis  
186 that CASC3 is required for efficient execution of NMD. Accordingly, several upregulated genes  
187 belong to the class of small RNA (e.g. snoRNA) host genes, which are frequently NMD targets  
188 (Figure 3C and D) (Lykke-Andersen *et al.*, 2014). We validated the upregulation of the snoRNA host  
189 gene ZFAS1 by qPCR, which was even more pronounced in CASC3 KO than UPF1 knockdown cells  
190 (Supplementary Figure 3D and E). Across the top 100 significantly upregulated genes in CASC3 KO,  
191 15 small RNA host genes were identified (Figure 3D). Comparing the differentially expressed genes  
192 to recent transcriptome-wide NMD screens, many of the top 100 significantly upregulated genes  
193 were also differentially expressed in UPF1 and SMG6/7 KD (Figure 3D, 23% and 59%, respectively)  
194 (Colombo *et al.*, 2017, Data ref: Colombo *et al.*, 2017). However, none of the identified targets  
195 were present in an RNPS1 knockdown (Figure 3D) (Boehm *et al.*, 2018, Data ref: Boehm *et al.*,  
196 2018). Collectively, our differential gene expression analysis strengthens the proposed link  
197 between CASC3 and the NMD-machinery.

198 Next, we analyzed alternative splicing changes in CASC3 KO cells (Figure 3A). Since our earlier  
199 assays showed that CASC3 was not involved in EJC-regulated splicing (Figures 1 and 2), we were  
200 surprised to detect many altered splicing events in CASC3 depleted cells (Supplementary Figure 3F,  
201 Supplementary Table 5). It is remarkable that hardly any alternative splicing events were shared  
202 between RNPS1 knockdown and CASC3 KO cells (Figure 3E, Supplementary Figure 3F). Either  
203 CASC3 regulates an RNPS1-independent set of alternative splice sites or the splicing changes are  
204 due to impaired NMD, which fails to remove NMD-sensitive isoforms. To test these possibilities,  
205 we investigated the functional consequence of CASC3-dependent alternatively splicing on the  
206 transcript isoform level (Figure 3A, Supplementary Figure 4A and B, and Supplementary Table 6).

207 Strikingly, in all CASC3 KO conditions the majority of upregulated mRNA isoforms contained a  
208 premature termination codon (PTC), rendering the transcripts susceptible to NMD (Figure 4A). On

209 the other hand, downregulated isoforms rarely contained a PTC. Among the identified isoform  
210 switches was the NMD target SRSF2, which we confirmed earlier to be CASC3-dependent (Figure  
211 1D). While overall SRSF2 gene expression varied only slightly between wild-type and CASC3 KO  
212 cells, the isoform usage changed dramatically towards the accumulation of NMD-sensitive  
213 transcripts in the CASC3 KO conditions (Figure 4B).

214 We next validated a set of transcript isoform switches by qPCR (Figure 4C-E, Supplementary Figure  
215 C and D). In the transcript isoforms stabilized by the CASC3 KO and by a UPF1 KD, the inclusion of  
216 intronic regions resulted in the inclusion of PTCs. For example, an NMD-sensitive transcript variant  
217 of the gene TOE1 is produced alongside the canonical isoform by usage of an alternative 3' splice  
218 site (Supplementary Figure 4D). This event was also prominently detected in the SMG6/7 and UPF1  
219 dataset (Supplementary Figure 4E).

220 The shift of isoform usage from NMD-insensitive to PTC-containing transcripts was also observed  
221 transcriptome-wide in CASC3 KO cells and was comparable to NMD-compromised SMG6/7 or UPF1  
222 depleted cells (Figure 4F). These findings indicate that many transcript isoforms upregulated upon  
223 depletion of CASC3 represent genuine endogenous NMD targets. On the gene level, nearly 50% of  
224 CASC3-dependent alternatively used transcript isoforms were also found in the SMG6/7 or UPF1  
225 conditions (Figure 4G and Supplementary Figure 4F). The incomplete overlap between CASC3 and  
226 SMG6/7 or UPF1 could be due to technical differences of the data sets or because not all NMD  
227 sensitive transcripts in the cell are affected by a knockout of CASC3. This could include transcripts  
228 that are degraded by EJC-independent NMD (Buhler *et al.*, 2006, Metze *et al.*, 2013).

229 ***CASC3 stimulates SMG6-dependent endocleavage***

230 To deepen the understanding of how a lack of CASC3 results in reduced NMD efficiency, we  
231 stably integrated the well-established globin NMD reporter PTC39 in WT and CASC3 KO cell lines  
232 (Figure 5A and B, Supplementary Figure 5A) (Thermann *et al.*, 1998). The analysis of a reporter  
233 mRNA enables a read-out of multiple aspects of mRNA degradation: firstly, the total levels of the

234 full-length reporter, secondly the contribution of 5'->3' exonucleolytic decay by XRN1 (detection  
235 of xrFrag due to an XRN1-resistant element (Boehm *et al.*, 2016, Voigt *et al.*, 2019); and thirdly the  
236 amount of endonucleolytic cleavage by SMG6 (detection of 3' fragment stabilized by XRN1  
237 knockdown). In both WT and CASC3 KO cell lines the reporter was efficiently degraded, showing  
238 that the NMD pathway is still functional in CASC3 depleted cells. However, full-length reporter  
239 levels in CASC3 KO were slightly higher when compared to wild-type cells (lane 2 vs. lane 5).  
240 Notably, the accumulation of 3' fragments following XRN1 knockdown was clearly reduced in the  
241 CASC3 KO condition (lane 3 vs. lane 6). This difference in endocleavage efficiency was also  
242 observed when expressing a minigene reporter of the endogenous CASC3 target TOE1. While there  
243 was a substantial upregulation of full-length reporter mRNA in CASC3 KO cells, the amount of the  
244 3' fragment was strongly reduced, suggesting that SMG6-dependent endocleavage is inefficient in  
245 CASC3 KO cells (Figure 5C and D, Supplementary Figure 5B-D). To further address this, a TPI  
246 reporter was expressed in combination with knockdowns of XRN1, SMG6 and/or SMG7 (Figure 5E-  
247 G). The degree of reporter and 3' fragment stabilization of the TPI reporter following XRN1  
248 knockdown was comparable to the observations made for the globin reporter (lanes 1-3 vs. lanes  
249 6-8). In both WT and CASC3 KO cells, SMG6 knockdown resulted in a drastic reduction of 3'  
250 fragments, as expected (lanes 4 and 9). Notably, a knockdown of SMG7 together with XRN1  
251 revealed a major difference between the cell lines. In WT cells the PTC-containing reporter was  
252 only minimally stabilized by the SMG7/XRN1 knockdown and 3' fragments were unaffected.  
253 Performing a SMG6/XRN1 knockdown in CASC3 KO cells lead to a more dramatic stabilization of  
254 the full-length reporter and a decrease of 3' fragments compared to the XRN1 knockdown  
255 condition (lanes 3 and 5 vs. lanes 8 and 10). Collectively, our results indicate that in CASC3 KO cells  
256 SMG6-mediated endocleavage is impaired. This could explain why the CASC3 KO cells are more  
257 sensitive to a knockdown of SMG7 when compared to wild type cells.

258 To identify, which part of CASC3 promotes NMD, we employed a tethering reporter that was  
259 designed to monitor mRNA turnover as well as endocleavage at the termination codon (Figure 6A).

260 Tethering the full-length CASC3 protein to the MS2 stem loops downstream of the stop codon  
261 resulted in degradation of the reporter compared to tethering of the negative control GST (Figure  
262 6B and C, Supplementary Figure 6A). This degradation was accompanied by the production of 3'  
263 fragments in XRN1 knockdown conditions, indicating that the mechanism of decay is comparable  
264 to the PTC-containing reporter mRNAs (Figure 6B, lane 6). Surprisingly, C-terminally truncated  
265 deletion mutants of CASC3 that contain the first 480 or even 137 amino acid residues were able to  
266 induce degradation of the tethering reporter to a comparable extent as full-length CASC3 (Figure  
267 6B, lanes 3 and 4, 7 and 8).

268 Finally, CASC3 deletion mutants were expressed in the CASC3 KO cells to identify the minimal  
269 part necessary to rescue the effects on endogenous NMD targets (Figure 6D, Supplementary Figure  
270 6B and C). As in the tethering experiment, expression of full-length CASC3 and the C-terminal  
271 truncated variant 1-480 resulted in transcript isoform levels comparable to wild-type cells for the  
272 targets CLN6 and TOE1 (Figure 6D lanes 1-4). An EJC binding-deficient mutant of CASC3 (188/218  
273 double point mutation) was unable to rescue, supporting the notion that CASC3 is recruited to the  
274 mRNA by binding to the EJC (Figure 6D, lane 5). Deleting the N-terminal 109 amino acids of CASC3  
275 (110-480) did not alter the rescue ability (Figure 6D, lane 6). While in the tethering assay it was  
276 sufficient to place the N-terminus downstream of a termination codon, this part of CASC3 was not  
277 necessary to rescue NMD activity in the KO cells. This suggests that different domains of CASC3 act  
278 in a redundant manner during the activation of NMD by the EJC.

279 **Discussion**

280 The role of CASC3 within the EJC has been the subject of scientific controversy for many years.  
281 CASC3 has been initially described as an EJC core protein, because it was required for the assembly of  
282 the EJC from recombinant protein components *in vitro* (Ballut *et al.*, 2005). However, it has been  
283 demonstrated that the mechanism of EJC assembly using recombinant proteins is mechanistically  
284 different from EJC assembly in splicing extracts or in living cell (Steckelberg *et al.*, 2012). Furthermore,  
285 several recent publications challenged the view of CASC3 being an EJC core component. For instance,  
286 CASC3 was reported to be present in substoichiometric amounts compared to the other three EJC core  
287 proteins EIF4A3, RBM8A, and MAGOH in HEK293 (Singh *et al.*, 2012) and U2OS cells (Beck *et al.*, 2011).  
288 Also, during mouse embryonic brain development CASC3 deficiency results in a different phenotype  
289 than the other EJC core components (Mao *et al.*, 2017). By using CASC3 CRISPR-Cas9 knockout cells,  
290 we unambiguously establish that CASC3 is not required for EJC assembly or EJC-regulated splicing in  
291 the nucleus (Figure 7). Therefore, our molecular analyses fully support the recently emerging view of  
292 defining CASC3 as a peripheral EJC component. As a mainly cytoplasmic component of the EJC we  
293 propose that the principal role of CASC3 is to alter the efficiency by which NMD-sensitive transcript  
294 isoforms are degraded.

295 Although NMD has been extensively studied in the past decades and many NMD factors have been  
296 identified and characterized, no universal model exists that describes how they work together to elicit  
297 NMD. While a function of CASC3 in NMD has been reported before, previous analyses did not show  
298 consistent results, ranging from a substantial contribution of CASC3 to only a minor role in NMD  
299 (Palacios *et al.*, 2004, Gehring *et al.*, 2005, Gehring *et al.*, 2009, Mabin *et al.*, 2018). In addition, none  
300 of the previous publications performed transcriptome-wide analyses but concentrated on reporter  
301 mRNAs of only a few selected endogenous NMD targets. We reasoned that the inconsistent results in  
302 the literature may be influenced by variable CASC3 knockdown efficiency. By generating CASC3  
303 knockout cell lines, we can for the first time analyze the global effects of a complete depletion of CASC3  
304 on the transcriptome and can exclude that residual CASC3 protein masks these effects. Interestingly,

305 the CASC3 knockout had no deleterious effect on the viability of HEK293 cells, unlike the depletion of  
306 the EJC components EIF4A3, RBM8A, or MAGOH. Nonetheless, since CASC3 is required for mouse  
307 embryogenesis and involved in the transport of mRNAs in *D. melanogaster*, it is likely that CASC3  
308 downregulation in highly specialized cell types such as neurons or in developing tissues would result  
309 in a more severe phenotype compared to HEK293 cells.

310 In recent years, high-throughput RNA-sequencing became an increasingly important method for  
311 the analysis of NMD. Several RNA-Seq datasets of cells with NMD-factor knockdowns have been  
312 generated and analyzed (Tani *et al.*, 2012, Hurt *et al.*, 2013, Lykke-Andersen *et al.*, 2014, Schmidt *et*  
313 *al.*, 2015, Colombo *et al.*, 2017). However, these datasets were obtained in different cell lines, with  
314 different amounts of replicates and due to the rapid developments of next-generation sequencing, not  
315 using the same technologies. Furthermore, batch effects and divergent approaches of data analyses  
316 may contribute to the fact that only a minor overlap of NMD targets could be established so far  
317 (Colombo *et al.*, 2017). We compared the results of our CASC3 KO RNA-sequencings to the most recent  
318 and comprehensive NMD factor analysis performed by Colombo *et al.* (2017). The differential  
319 expression analysis revealed that many of the top upregulated genes in the CASC3 KO datasets are also  
320 significantly affected by UPF1 or SMG6/7 knockdowns (Colombo *et al.*, 2017) and/or encode for small  
321 RNA (sRNA) host genes, a previously described class of NMD targets (Lykke-Andersen *et al.*, 2014).

322 We detected many alternative splicing events in the CASC3 KO data, which was unexpected given  
323 that CASC3 was apparently dispensable for the nuclear EJC-related functions. However, we could  
324 attribute these splicing patterns to dysfunctional NMD, since isoform-specific algorithms revealed that  
325 predominantly PTC-containing transcripts accumulated. Using all the available bioinformatics analysis  
326 pipelines and a systematic approach to detect affected transcripts under NMD factor  
327 knockdown/knockout conditions could therefore be a crucial step to paint a complete picture of the  
328 regulation of transcripts by NMD in the future.

329 How exactly CASC3 activates NMD when bound to an EJC, is not yet fully understood. Previously,  
330 we reported that the presence of EJCs in the 3' UTR enhances endocleavage (Boehm *et al.*, 2014). In  
331 line with the proposed role as a peripheral NMD-activating EJC component, we observed that CASC3  
332 stimulates SMG6-dependent endocleavage, thereby promoting the degradation of NMD-targeted  
333 transcripts. This effect can be recapitulated by tethering full-length CASC3, its N-terminal two thirds  
334 (1-480) or just its N-terminal 137 amino acids to a reporter mRNA. How the small N-terminal region,  
335 which cannot assemble into the EJC or contains any known protein domains or sequence motifs can  
336 elicit NMD remains to be determined. It is also unclear, if the N-terminus activates translation-  
337 dependent degradation, as it was previously shown for the full length CASC3 (Boehm *et al.*, 2016).  
338 Since the N-terminal segment of CASC3 is a region of low-complexity it could hypothetically undergo  
339 liquid-liquid phase separation (LLPS) and be present in condensates with mRNA decay factors, such as  
340 processing bodies (P-bodies). In agreement with this idea CASC3 was shown to localize to cytoplasmic  
341 granules when overexpressed (Cougot *et al.*, 2014).

342 Our data suggest that CASC3 activates NMD by potentially redundant mechanisms. This fits very  
343 well into the general picture of NMD, which uses multiplexed degradation pathways to efficiently and  
344 robustly remove mRNAs. Mechanistically, binding of CASC3 to the EJC could have an indirect effect on  
345 NMD stimulation by increasing the stability of the bound EJC and thus maintaining the possibility of  
346 efficient endonucleolytic cleavage of the transcript. An indication for this role comes from the initial *in*  
347 *vitro* observation that CASC3 stabilizes recombinant EJCs (Ballut *et al.*, 2005). Additionally, the  
348 moderately reduced pull-down of UPF3B with EIF4A3 could indicate that cytoplasmic NMD-competent  
349 EJCs are less stable in CASC3 KO cells. Alternatively, CASC3 may directly contribute to the recruitment  
350 of NMD factors. We therefore propose that CASC3 either alone or in conjunction with UPF3B links the  
351 EJC with the NMD machinery. In particular, CASC3 influences the contribution of SMG6-mediated  
352 endonucleolytic and SMG7-dependent exonucleolytic decay pathways to the overall degradation  
353 efficiency of NMD. Accordingly, in wild type cells a knockdown of SMG7 only had a marginal effect on  
354 the abundance of the analyzed NMD reporter mRNA, whereas it clearly impaired NMD in CASC3 KO

355 cells. Also, the amount of endocleavage-derived 3' fragments was reduced when CASC3 is depleted,  
356 mirroring the SMG6-knockdown condition.

357 By integrating CASC3 as a specific NMD-activating factor we can now postulate a modified model  
358 of EJC-dependent NMD, which is also compatible with several molecular properties of the EJC (Figure  
359 7). Since CASC3 is only present in modest amounts in the cytoplasm, it will probably not immediately  
360 associate with all EJCs on recently exported mRNPs. This would also not be necessary, since most EJCs  
361 are located in the coding sequence and will therefore be removed by the first translating ribosome.  
362 However, mRNAs containing PTCs will carry one or more EJCs in their 3' UTR, which are available for  
363 binding of CASC3. The first few translating ribosomes may terminate upstream of CASC3-free EJCs,  
364 which could preferentially trigger SMG7-dependent exonucleolytic degradation. Previously, NMD has  
365 been proposed to occur primarily in the pioneering round of translation when newly synthesized  
366 transcripts are bound to the cap-binding complex (Ishigaki *et al.*, 2001, Maquat *et al.*, 2010). This model  
367 has been challenged and there is evidence that NMD can occur on already translating mRNAs and  
368 possibly with a constant probability during every round of translation (Durand & Lykke-Andersen,  
369 2013, Rufener & Muhlemann, 2013, Hoek *et al.*, 2019). Thus, CASC3 could bind to the EJC at a later  
370 time point and then increase the probability to activate SMG6-mediated endonucleolytic degradation  
371 after each round of termination. Important molecular targets of CASC3 may be mRNAs that escape  
372 initial NMD activation, despite containing a PTC (Trcek *et al.*, 2013, Hoek *et al.*, 2019). CASC3 may help  
373 to reduce the amount of these mRNAs by maintaining the NMD-activating function of the EJC, either  
374 by increasing its stability on the mRNA or via direct interactions with the NMD machinery. This concept  
375 would be consistent with the recent observation that NMD targets undergo several rounds of  
376 translation before endocleavage occurs (Hoek *et al.*, 2019).

377 In summary, our data paint a picture, in which CASC3 has no essential EJC-related function in the  
378 nucleus, but helps to turn EJCs into a persistent RNA degradation mode. We do not exclude the  
379 possibility that CASC3 is already associated with the EJC in the nucleus. However, our model of delayed

380 binding of CASC3 to the EJC in the cytoplasm would explain why only a small amount of CASC3 is  
381 sufficient to activate EJC-dependent NMD. In this model, CASC3 is an indispensable cytoplasmic  
382 component of the EJC that helps to degrade mRNAs that failed to unload all their bound EJCs during  
383 the initial rounds of translation. Thus, the binding of CASC3 to the EJC could signal the final round(s) of  
384 translation of an mRNA.

385 **Materials and Methods**

386 **Cell culture**

387 Flp-In 293 T-REx cells (Thermo Fisher Scientific) were maintained at 37°C, 5% CO<sub>2</sub> and  
388 90% humidity in Dublecco's Modified Eagle Medium (DMEM, Thermo Fisher Scientific) supplemented  
389 with 9% fetal bovine serum (FBS) and Penicillin-Streptomycin (both Thermo Fisher Scientific).  
390 Tethering experiments were performed in HeLa Tet-Off cells (Clontech) cultured in the same  
391 conditions.

392 **siRNA-mediated knockdowns**

393 The cells were seeded in 6-well plates at a density of 2x10<sup>5</sup> cells per well and reverse transfected  
394 using 2.5 µl Lipofectamine RNAiMAX and 60 pmol of the respective siRNA(s) according to the  
395 manufacturer's instructions. In preparation for mass spectrometry, the cells were reverse transfected  
396 in 10 cm dishes using 10 µl Lipofectamine RNAiMAX and 300 pmol siRNA. siRNAs were targeted against  
397 Luciferase (5'-CGTACGCGGAATACTTCGA-3'), EIF4A3 (5'-AGACATGACTAAAGTGGAA-3'), RBM8A (5'-  
398 TTCGCAGAATATGGGAAA-3'), CASC3 (5'-CTGATGACATCAAACCTCGAAGAAT-3', 5'-  
399 CGTCATGAACTTGGTAATCCCAGT-3'), UPF1 (5'-GATGCAGTTCCGCTCCATT-3'), XRN1 (5'-  
400 AGATGAACTTACCGTAGAA-3'), SMG6 (5'-GGGTCACAGTGCTGAAGTA-3') or SMG7 (5'-  
401 CGATTGGAATACGCTTTA-3').

402 **Generation of knockout cells using CRISPR-Cas9**

403 The knockouts were performed using the Alt-R CRISPR-Cas9 system (IDT) and reverse transfection  
404 of a Cas9:guideRNA ribonucleoprotein complex using Lipofactamine RNAiMAX (Thermo Fisher  
405 Scientific) according to the manufacturer's protocol. The crRNA sequences to target CASC3 were  
406 /A/ITR1/rGrCrGrCrGrCrUrUrCrGrCrArArGrArCrArCrGrGrUrUrUrArGrArGrCrUrArUrGrCrU/A/ITR2/  
407 (clone H) and  
408 /A/ITR1/rGrUrUrCrGrCrCrUrCrCrGrCrUrGrUrGrArGrUrUrArGrArGrCrUrArUrGrCrU/A/ITR2/  
409 (clones F and T). Reverse transfection was performed on 1.5x10<sup>5</sup> cells per crRNA in 12-well dishes.

410 48 hours after transfection the cells were trypsinized, counted and seeded at a density of a single cell  
411 per well in 96-well plates. Cell colonies originating from a single clone were then validated by Sanger  
412 sequencing of the targeted genomic DNA locus and western blotting.

413 ***Plasmid transfection***

414 All used plasmids are listed in Supplementary Table 1. To express FLAG-tagged protein constructs  
415 and the reporter mRNAs detected by northern blotting, the cells were stably transfected using the Flp-  
416 In T-REx system and the tetracycline inducible pCDNA5/FRT/TO vector (Thermo Fisher Scientific). The  
417 constructs TPI-WT, TPI-PTC,  $\beta$ -globin WT and  $\beta$ -globin PTC are available on Addgene (IDs 108375-  
418 108378).  $2.5 \times 10^5$  cells were seeded 24 h before transfection in 6-wells. Per well, 1  $\mu$ g of reporter  
419 construct was transfected together with 1  $\mu$ g of the Flp recombinase expressing plasmid pOG44 using  
420 the calcium phosphate method. 48 h after transfection, the cells were transferred into 10 cm dishes  
421 and selected with 100  $\mu$ g/ml hygromycin. After 10 days, the colonies were pooled. Expression of the  
422 reporter mRNA was induced with 1  $\mu$ g/ml doxycycline for 24 h.

423 Constructs that express V5-tagged and MS2V5-tagged proteins were stably integrated into the  
424 cells using the PiggyBac (PB) Transposon system and the cumate-inducible PB-CuO-MCS-IRES-GFP-EF1-  
425 CymR-Puro vector (System Biosciences).  $2.5 \times 10^5$  cells were seeded 24 h before transfection in 6-wells.  
426 2.5  $\mu$ g of the PB Transposon vector and 0.8  $\mu$ g of PB Transposase were transfected per well using the  
427 calcium phosphate method. After 48 h, the cells were pooled in 10 cm dishes and positive clones  
428 selected with 2  $\mu$ g/ml puromycin for a week. Expression of proteins was induced using 30  $\mu$ g/ml  
429 cumate for 72 h.

430 The tethering construct pSBtet-Hyg-TPI-4MS2-SMG5-4H was stably integrated into HeLa Tet-Off  
431 cells using the Sleeping Beauty (SB) transposon system (Mates *et al.*, 2009, Kowarz *et al.*, 2015). pSBtet-  
432 Hyg was a gift from Eric Kowarz (Addgene plasmid #60508; <http://n2t.net/addgene:60508>;  
433 RRID:Addgene\_60508). pCMV(CAT)T7-SB100 was a gift from Zsuzsanna Izsvák (Addgene plasmid  
434 #34879; <http://n2t.net/addgene:34879>; RRID:Addgene\_34879).  $2.5 \times 10^5$  cells were seeded 24 h before

435 transfection in 6-wells. Per well, 1 µg of the reporter construct was transfected together with 1.5 µg  
436 of the SB Transposase using the calcium phosphate method. 48 h after transfection, the cells were  
437 transferred into 10 cm dishes and selected with 100 µg/ml hygromycin. After 10 days, the colonies  
438 were pooled. In absence of tetracycline the reporter was constitutively expressed.

439 *RNA-Sequencing and computational analyses*

440 RNA-Seq analysis was carried out with 293 WT cells transfected with Luciferase siRNA and the  
441 CASC3 KO clones H and T transfected with either Luciferase or CASC3 siRNAs. Three biological  
442 replicates were analyzed for each sample. RNA was isolated with the kit NucleoSpin RNA Plus  
443 (Macherey-Nagel). The Lexogen SIRV Set1 Spike-In Control Mix (SKU: 025.03) that provides a set of  
444 external RNA controls was added to the total RNA to enable performance assessment. Mix 0 was added  
445 to replicate 1, mix 1 was added to replicate 2 and mix 3 to replicate 3. The Spike-Ins were not used for  
446 analysis. The library preparation was performed with the TrueSeq Stranded Total RNA kit (Illumina).  
447 First steps of the library preparation involve the removal of ribosomal RNA using biotinylated target-  
448 specific oligos combined with Ribo-Zero gold rRNA removal beads from 1ug total RNA input. The Ribo-  
449 Zero Human/Mouse/Rat kit depletes samples of cytoplasmic and mitochondrial rRNA. Following  
450 purification, the RNA is fragmented and cleaved. RNA fragments are copied into first strand cDNA using  
451 reverse transcriptase and random primers, followed by second strand cDNA synthesis using DNA  
452 Polymerase I and RNase H. These cDNA fragments then have the addition of a single 'A' base and  
453 subsequent ligation of the adapter. The products are purified and enriched with PCR to create the final  
454 cDNA library. After library validation and quantification (Agilent tape station), equimolar amounts of  
455 library were pooled. The pool was quantified by using the Peqlab KAPA Library Quantification Kit and  
456 the Applied Biosystems 7900HT Sequence Detection System and sequenced on an Illumina  
457 NovaSeq6000 sequencing instrument and an PE100 protocol.

458 Read processing and alignment was performed as described previously (Boehm *et al.*, 2018). In  
459 short, adaptor sequences and low quality bases were removed with Flexbar 3.0 (Dodd *et al.*, 2012).

460 Short reads from the rRNA locus were subtracted by mapping against the 45S precursor (*Homo*  
461 *sapiens*, NR\_046235.1) using Bowtie2 (Langmead & Salzberg, 2012). The remaining reads were aligned  
462 against the human genome (version 38, EnsEMBL 90 transcript annotations) using the STAR read  
463 aligner (version 2.5.3a) (Dobin *et al.*, 2013).

464 To compute gene differential expression analysis, reads covering exons were counted with  
465 FeatureCounts (version 1.5.1) (Liao *et al.*, 2014) using the ‘—primary’ and ‘—ignoreDup’ parameters.  
466 Differential gene expression analysis was performed with DESeq2 (Love *et al.*, 2014, Ignatiadis *et al.*,  
467 2016) and IWH R packages. Significance thresholds were  $|\log_{2}\text{FoldChange}| > 1$  and adjusted p-value  
468 ( $\text{padj} < 0.05$ ). Genes were designated as small RNA (sRNA) host gene, if they contained other Ensembl-  
469 annotated genes of biotypes snoRNA or miRNA within their genomic coordinates (Zerbino *et al.*, 2018).

470 Differential splicing was detected with LeafCutter (version 0.2.7) (Li *et al.*, 2018) with the  
471 parameters  $\text{min\_samples\_per\_intron} = 2$  and  $\text{min\_samples\_per\_group} = 2$ . Significance thresholds  
472 were  $|\text{deltapsi}| > 0.1$  and adjusted p-value ( $\text{p.adjust} < 0.05$ ).

473 Transcript abundance estimates were computed with Salmon (version 0.13.1) (Patro *et al.*, 2017)  
474 using the the -validateMappings --gcBias parameters. Differential transcript usage was computed with  
475 IsoformSwitchAnalyzeR (version 1.7.1) and the DEXSeq method (Robinson & Oshlack, 2010, Anders *et*  
476 *al.*, 2012, Ritchie *et al.*, 2015, Soneson *et al.*, 2015, Vitting-Seerup & Sandelin, 2017, Vitting-Seerup &  
477 Sandelin, 2019). Significance thresholds were  $|\text{dIF}| > 0.1$  and adjusted p-value  
478 ( $\text{isoform\_switch\_q\_value} < 0.05$ ). For the Boxplot and Kolmogorov-Smirnoff test, the data were filtered  
479 only for the adjusted p-value. PTC status of transcript isoforms with annotated open reading frame  
480 was determined by IsoformSwitchAnalyzeR using the 50 nt rule of NMD (Weischenfeldt *et al.*, 2012,  
481 Vitting-Seerup *et al.*, 2014, Huber *et al.*, 2015, Vitting-Seerup & Sandelin, 2017). Isoforms with no  
482 annotated open reading frame in Ensembl were designated “NA” in the PTC analysis.

483 The UPF1 and SMG6/7 (Data ref: Colombo *et al.*, 2017) and RNPS1 (Data ref: Boehm *et al.*, 2018)  
484 knockdown datasets were processed and analyzed with the same programs, program versions, and

485 scripts as the CASC3 dataset. All packages used are listed in the respective analysis table  
486 (Supplementary Tables 4-6). Sashimi plots were generated using ggsashimi (Garrido-Martin *et al.*,  
487 2018). Overlaps of data sets were represented via nVenn (Perez-Silva *et al.*, 2018), eulerr (Larsson,  
488 2019) and Upset plots (Lex *et al.*, 2014). Heatmaps were generated using ComplexHeatmap (Gu *et al.*,  
489 2016).

490 ***SILAC, co-immunoprecipitation and mass spectrometry***

491 293 WT and 293 CASC3 KO clone H cells expressing either FLAG or FLAG-EIF4A3 were labeled by  
492 maintaining them for 5 passages in DMEM for SILAC medium (Thermo Fisher Scientific) supplemented  
493 with FBS (Silantes), Penicillin-Streptomycin (Thermo Fisher Scientific) and the respective amino acids  
494 at a final concentration of 0.798 mmol/L (Lysine) and 0.398 (Arginine). Unlabeled proline was added  
495 to prevent enzymatic Arginine-to-Proline conversion. The conditions were “light” (unlabeled  
496 Lysine/Arginine), “medium” (Lysine 4/Arginine 6) and “heavy” (Lysine 8/Arginine 10). A label switch  
497 was performed between the three replicates according to the experimental setup listed in  
498 Supplementary Table 2. The expression of FLAG or FLAG-EIF4A3 was induced for 72 h with 1 µg/ml  
499 doxycycline. The cells were lysed in buffer E with RNase (20 mM HEPES-KOH (pH 7.9), 100 mM KCl,  
500 10% glycerol, 1 mM DTT, Protease Inhibitor, 1 µg/ml RNase A) and sonicated using the Bandelin  
501 Sonopuls mini20 with 15 pulses (2.5 mm tip in 600 µl volume, 1s, 50% amplitude). 600 µl of a 1.6 mg/ml  
502 total protein lysate were incubated with 30 µl Anti-FLAG M2 magnetic beads (Sigma) at 4° C while  
503 rotating for 2 h. The beads were washed three times for 5 min with EJC-buffer (20 mM HEPES-KOH (pH  
504 7.9), 200 mM NaCl, 2 mM MgCl<sub>2</sub>, 0.2% Triton X-100, 0.1% NP-40, 0.05% Sodium deoxycholate) and  
505 eluted in 43 µl of a 200 mg/ml dilution of FLAG peptides (Sigma) in 1x TBS. The samples were merged  
506 according to Supplementary Table 2. 1 volume of 10% SDS was added and the samples were reduced  
507 with DTT and alkylated with CAA (final concentrations 5 mM and 40 mM, respectively). Tryptic protein  
508 digestion was performed using a modified version of the single pot solid phase-enhanced sample  
509 preparation (SP3) (Hughes *et al.*, 2014). In brief, reduced and alkylated proteins were supplemented  
510 with paramagnetic Sera-Mag speed beads (Thermo Fisher Scientific) and mixed in a 1:1-ratio with 100%

511 acetonitrile (ACN). After 8 min incubation protein-beads-complexes were captured using an in-house  
512 build magnetic rack and two times washed with 70% EtOH. Afterwards, samples were washed once  
513 with 100% ACN, air-dried and reconstituted in 5  $\mu$ l 50 mM Triethylammonium bicarbonate  
514 supplemented with 0.5  $\mu$ g trypsin and 0.5  $\mu$ g LysC and incubated overnight at 37°C. On the next day  
515 the beads were resuspended and mixed with 200  $\mu$ l ACN, incubated for 8 min and again placed on the  
516 magnetic rack. Tryptic peptides were washed once with 100% ACN, airdried, dissolved in 4% DMSO  
517 and transferred into 96-well PCR tubes. After acidification with 1  $\mu$ l of 10% formic acid, samples were  
518 ready for LC-MS/MS analysis

519 For the MS experiment combined with CASC3 knockdown, the 293 CASC3 KO clone H cells were  
520 treated with siRNA against CASC3 24 h before expression of the FLAG-tagged construct. The cells were  
521 lysed and samples prepared for MS as described above. However, the washing steps were performed  
522 in a less stringent EJC buffer (20 mM HEPES-KOH (pH 7.9), 137 mM NaCl, 2 mM MgCl<sub>2</sub>, 0.2% Triton X-  
523 100, 0.1% NP-40).

524 Proteomics analysis was performed by data-dependent acquisition using an Easy nLC1200 ultra  
525 high-performance liquid chromatography (UHPLC) system coupled via nanoelectrospray ionization to  
526 a Q Exactive Plus instrument (all Thermo scientific). Tryptic peptides were separated based on their  
527 hydrophobicity using a chromatographic gradient of 60 min with a binary system of buffer A (0.1%  
528 formic acid) and buffer B (80% ACN, 0.1% formic acid). In-house made analytical columns (length: 50  
529 cm, inner diameter: 75  $\mu$ m) filled with 1.9  $\mu$ m C18-AQ Reprosil Pur beads (Dr. Maisch) were used for  
530 separation. Buffer B was linearly increased from 3% to 27% over 41 min followed by a steeper increase  
531 to 50% within 8 min. Finally, buffer B was increased to 95% within 1 min and stayed at 95% for 10 min  
532 in order to wash the analytical column. Full MS spectra (300 – 1,750 m/z) were acquired with a  
533 resolution of 70,000, a maximum injection time of 20 ms and an AGC target of 3e6. The top 10 most  
534 abundant peptide ions of each full MS spectrum were selected for HCD fragmentation (NCE: 27) with

535 an isolation width of 1.8 m/z and a dynamic exclusion of 10 seconds. MS/MS spectra were measured  
536 with a resolution of 35,000, a maximum injection time of 110 ms and an AGC target of 5e5.

537 MS RAW files were analysed using the standard settings of the MaxQuant suite (version 1.5.3.8)  
538 with the before mentioned SILAC labels (Cox & Mann, 2008). Peptides were identified by matching  
539 against the human UniProt database using the Andromeda scoring algorithm (Cox *et al.*, 2011).  
540 Carbamidomethylation of cysteine was set as a fixed modification, methionine oxidation and N-  
541 terminal acetylation as variable modification. Trypsin/P was selected as digestion protein. A false  
542 discovery Rate (FDR) < 0.01 was used for identification of peptide-spectrum matches and protein  
543 quantification. Data processing and statistical analysis was done in the Perseus software (version  
544 1.5.5.3) (Tyanova *et al.*, 2016). Significantly changed proteins were identified by One-sample t-testing  
545 ( $H_0 = 0$ , fudge factor  $S_0 = 0.1$ ). The results are listed in Supplementary Table 2 as “Results without  
546 knockdown” (MAP conditions) and “Results with knockdown”. Visualization was performed with the  
547 Instant Clue software (version 0.5.3) (Nolte *et al.*, 2018).

548 Co-immunoprecipitation experiments followed by western blotting were performed as described  
549 above except that a 15 min incubation step in SDS buffer (600 mM Tris pH 6.8, 100 mM DTT, 10%  
550 Glycerol, 2% SDS, 0.002% Bromophenolblue) was used for elution from the beads.

551 *In vitro splicing assay*

552 FLAG-emGFP and FLAG-EIF4A3 was expressed in 293 WT and 293 CASC3 KO clone H cells for 72 h.  
553 Whole cell lysate preparation and *in vitro* splicing was performed as previously described (Steckelberg  
554 & Gehring, 2014), however the nuclear extract was substituted with whole cell extract from the  
555 respective cell line. Pulldown efficiency of spliced mRNA was calculated by dividing the amount of  
556 spliced mRNA in the pulldown by the amount in the respective input and dividing the results by 10  
557 since 10% of the input was loaded.

558 *Semi-quantitative and quantitative reverse transcriptase (RT)-PCR*

559 RNA was extracted using peqGOLD TriFast reagent (VWR) according to the manufacturer's  
560 instructions. Reverse transcription was performed with GoScript Reverse Transcriptase (Promega)  
561 using 2 µg total RNA and oligo dT primers. Semi-quantitative PCR was carried out with MyTaq Red Mix  
562 (Bioline). Quantitative real time PCR was performed with 16 ng of cDNA per reaction with GoTaq qPCR  
563 Master Mix (Promega) and the CFX96 Touch Real-Time PCR Detection System (Biorad). The average cT  
564 values were calculated from three technical replicates. The mean fold changes from three biological  
565 replicates were calculated according to the  $\Delta\Delta Ct$  method (Schmittgen & Livak, 2008). When measuring  
566 isoform switches, the fold change of the PTC-containing transcript was normalized to the canonical  
567 transcript. When measuring differential expression, the fold change was normalized to GAPDH. For  
568 each primer pair amplification efficiencies were measured by a 2-fold dilution curve and ranged  
569 between 87 and 100.1%. The primer sequences are listed in Supplementary Table 3.

570 *Western blotting*

571 Protein extraction was performed with peqGOLD TriFast reagent (VWR), separated by SDS-PAGE  
572 gel electrophoresis and transferred to a PVDF membrane (GE Healthcare Life Sciences). The following  
573 antibodies were used: Anti- $\beta$ -actin (Sigma-Aldrich, #A5441), anti-CASC3 amino acid residues 653-703  
574 (Bethyl Laboratories, #A302-472A-M), anti-CASC3 amino acid residues 367-470 (Atlas Antibodies,  
575 #HPA024592), anti-EIF4A3 (Genscript), anti-FLAG (Cell Signaling Technology, #14793), anti-MAGOH  
576 (Santa Cruz Biotechnology, #sc-271365), anti-RBM8A (Atlas Antibodies, #HPA018403), anti-SMG6  
577 (Abcam, #ab87539), anti-SMG7 (Elabscience, #E-AB-32926), anti-Tubulin (Sigma-Aldrich, #T6074), anti-  
578 V5 (QED Bioscience, #18870), anti-XRN1 (Bethyl Laboratories, #A300-443A), anti-rabbit-HRP (Jackson  
579 ImmunoResearch, #111-035-006), anti-mouse-HRP (Jackson ImmunoResearch, #115-035-003).  
580 Detection was performed with Western Lightning Plus-ECL (PerkinElmer) or Amersham ECL prime (Ge  
581 Healthcare Life Sciences) and the chemiluminescence imager Fusion FX6 EDGE (Vilber-Lourmat).

582 *Northern blotting*

583 The cells were harvested in peqGOLD TriFast reagent (VWR) and total RNA extraction was  
584 performed as recommended by the manufacturer's protocol. 2.5 µg of total RNA were resolved on a  
585 1% agarose/0.4 M formaldehyde gel using the tricine/triethanolamine buffer system (Mansour &  
586 Pestov, 2013) followed by transfer on a nylon membrane (Roth) in 10x SSC. The blots were incubated  
587 overnight at 65 °C in Church buffer containing [ $\alpha$ -32P]-GTP body-labeled RNA probes for detection of  
588 the reporter mRNA. Endogenous 7SL RNA was detected by a 5'-32P-labeled oligonucleotide (5'-  
589 TGCTCCGTTCCGACCTGGGCCGGTCACCCCTCCTT-3'). The blots were visualized and quantified using a  
590 Typhoon FLA 7000 (GE Healthcare) and ImageQuant TL 1D software.

591 ***Data Availability***

592 The datasets produced in this study are available in the following databases. These data will be  
593 made publicly accessible upon publication.

594 • RNA-seq data have been deposited in the ArrayExpress database (Kolesnikov *et al.*, 2015) at  
595 EMBL-EBI under accession number E-MTAB-8461  
596 (<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8461>).  
597 • The mass spectrometry proteomics data have been deposited to the ProteomeXchange  
598 Consortium via the PRIDE (Perez-Riverol *et al.*, 2019) partner repository with the dataset  
599 identifier PXD015754 (<https://www.ebi.ac.uk/pride/archive/projects/PXD015754>).

600 ***Author Contributions***

601      Conceptualization, N.H.G., J.V.G. and V.B.;

602      Methodology, N.H.G., V.B., J.V.G., and C.K.F.;

603      Software, T.B.B., V.B., J.L.W., S.K. and C.D.;

604      Investigation, J.V.G, V.B., J.L.W., S.K., D.U.A. and S.C.;

605      Resources and Data Curation, T.B.B., J.L.W., S.K., J.A. and C.D.;

606      Writing – Original Draft, Review & Editing, N.H.G., J.V.G. and V.B.;

607      Visualization, J.V.G., V.B. and T.B.B.;

608      Supervision, N.H.G., C.D. and M.K.;

609      Funding Acquisition, N.H.G. and C.D.

610 ***Acknowledgements***

611      We thank members of the Gehring lab for discussions and reading of the manuscript. We also  
612      thank Marek Franitz and Christian Becker (Cologne Center for Genomics, CCG) for preparing the  
613      sequencing libraries and operating the sequencer. We acknowledge Tobias Jakobi for helping with  
614      infrastructure support. This work was supported by grants from the Deutsche Forschungsgemeinschaft  
615      to C.D. (DI 1501/8-1, DI1501/8-2) and N.H.G (GE 2014/6-1, GE 2014/6-2 and GE 2014/10-1). V.B. was  
616      funded under the Institutional Strategy of the University of Cologne within the German Excellence  
617      Initiative. N.H.G. acknowledges support by a Heisenberg fellowship (GE 2014/5-1 and GE 2014/7-1)  
618      from the Deutsche Forschungsgemeinschaft. C.D. and T.B.B. were kindly supported by the Klaus Tschira  
619      Stiftung gGmbH (00.219.2013)

620 ***Conflict of Interest***

621      The authors declare no competing interests.

622

## 623 *References*

624 Alexandrov A, Colognori D, Shu MD, Steitz JA (2012) Human spliceosomal protein CWC22 plays a role  
625 in coupling splicing to exon junction complex deposition and nonsense-mediated decay. *Proc Natl Acad  
626 Sci U S A* 109: 21313-8

627 Anders S, Reyes A, Huber W (2012) Detecting differential usage of exons from RNA-seq data. *Genome  
628 Res* 22: 2008-17

629 Andersen CB, Ballut L, Johansen JS, Chamieh H, Nielsen KH, Oliveira CL, Pedersen JS, Seraphin B, Le Hir  
630 H, Andersen GR (2006) Structure of the exon junction core complex with a trapped DEAD-box ATPase  
631 bound to RNA. *Science* 313: 1968-72

632 Ballut L, Marchadier B, Baguet A, Tomasetto C, Seraphin B, Le Hir H (2005) The exon junction core  
633 complex is locked onto RNA by inhibition of eIF4AIII ATPase activity. *Nat Struct Mol Biol* 12: 861-9

634 Barbosa I, Haque N, Fiorini F, Barrandon C, Tomasetto C, Blanchette M, Le Hir H (2012) Human CWC22  
635 escorts the helicase eIF4AIII to spliceosomes and promotes exon junction complex assembly. *Nat Struct  
636 Mol Biol* 19: 983-90

637 Beck M, Schmidt A, Malmstroem J, Claassen M, Ori A, Szymborska A, Herzog F, Rinner O, Ellenberg J,  
638 Aebersold R (2011) The quantitative proteome of a human cell line. *Mol Syst Biol* 7: 549

639 Bessonov S, Anokhina M, Will CL, Urlaub H, Luhrmann R (2008) Isolation of an active step I spliceosome  
640 and composition of its RNP core. *Nature* 452: 846-50

641 Boehm V, Britto-Borges T, Steckelberg AL, Singh KK, Gerbracht JV, Gueney E, Blazquez L, Altmuller J,  
642 Dieterich C, Gehring NH (2018) ArrayExpress E-MTAB-6564  
643 (<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6564>)

644 Boehm V, Britto-Borges T, Steckelberg AL, Singh KK, Gerbracht JV, Gueney E, Blazquez L, Altmuller J,  
645 Dieterich C, Gehring NH (2018) Exon Junction Complexes Suppress Spurious Splice Sites to Safeguard  
646 Transcriptome Integrity. *Mol Cell* 72: 482-495 e7

647 Boehm V, Gehring NH (2016) Exon Junction Complexes: Supervising the Gene Expression Assembly  
648 Line. *Trends Genet* 32: 724-735

649 Boehm V, Gerbracht JV, Marx MC, Gehring NH (2016) Interrogating the degradation pathways of  
650 unstable mRNAs with XRN1-resistant sequences. *Nat Commun* 7: 13691

651 Boehm V, Haberman N, Ottens F, Ule J, Gehring NH (2014) 3' UTR length and messenger  
652 ribonucleoprotein composition determine endocleavage efficiencies at termination codons. *Cell Rep*  
653 9: 555-68

654 Bono F, Ebert J, Lorentzen E, Conti E (2006) The crystal structure of the exon junction complex reveals  
655 how it maintains a stable grip on mRNA. *Cell* 126: 713-25

656 Buchwald G, Ebert J, Basquin C, Sauliere J, Jayachandran U, Bono F, Le Hir H, Conti E (2010) Insights  
657 into the recruitment of the NMD machinery from the crystal structure of a core EJC-UPF3b complex.  
658 *Proc Natl Acad Sci U S A* 107: 10050-5

659 Buhler M, Steiner S, Mohn F, Paillusson A, Muhlemann O (2006) EJC-independent degradation of  
660 nonsense immunoglobulin-mu mRNA depends on 3' UTR length. *Nat Struct Mol Biol* 13: 462-4

661 Colombo M, Karousis ED, Bourquin J, Bruggmann R, Muhlemann O (2017) Gene Expression Omnibus  
662 GSE86148 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86148>). [DATASET]

663 Colombo M, Karousis ED, Bourquin J, Bruggmann R, Muhlemann O (2017) Transcriptome-wide  
664 identification of NMD-targeted human mRNAs reveals extensive redundancy between SMG6- and  
665 SMG7-mediated degradation pathways. *RNA* 23: 189-201

666 Cougot N, Daguenet E, Baguet A, Cavalier A, Thomas D, Bellaud P, Fautrel A, Godey F, Bertrand E,  
667 Tomasetto C, Gillet R (2014) Overexpression of MLN51 triggers P-body disassembly and formation of  
668 a new type of RNA granules. *J Cell Sci* 127: 4692-701

669 Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range  
670 mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* 26: 1367-72

671 Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M (2011) Andromeda: a peptide search  
672 engine integrated into the MaxQuant environment. *J Proteome Res* 10: 1794-805

673 Degot S, Regnier CH, Wendling C, Chenard MP, Rio MC, Tomasetto C (2002) Metastatic Lymph Node  
674 51, a novel nucleo-cytoplasmic protein overexpressed in breast cancer. *Oncogene* 21: 4422-34

675 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013)  
676 STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29: 15-21

677 Dodt M, Roehr JT, Ahmed R, Dieterich C (2012) FLEXBAR-Flexible Barcode and Adapter Processing for  
678 Next-Generation Sequencing Platforms. *Biology (Basel)* 1: 895-905

679 Durand S, Lykke-Andersen J (2013) Nonsense-mediated mRNA decay occurs during eIF4F-dependent  
680 translation in human cells. *Nat Struct Mol Biol* 20: 702-9

681 Eberle AB, Lykke-Andersen S, Muhlemann O, Jensen TH (2009) SMG6 promotes endonucleolytic  
682 cleavage of nonsense mRNA in human cells. *Nat Struct Mol Biol* 16: 49-55

683 Garrido-Martin D, Palumbo E, Guigo R, Breschi A (2018) ggsashimi: Sashimi plot revised for browser-  
684 and annotation-independent splicing visualization. *PLoS Comput Biol* 14: e1006360

685 Gehring NH, Kunz JB, Neu-Yilik G, Breit S, Viegas MH, Hentze MW, Kulozik AE (2005) Exon-junction  
686 complex components specify distinct routes of nonsense-mediated mRNA decay with differential  
687 cofactor requirements. *Mol Cell* 20: 65-75

688 Gehring NH, Lamprinaki S, Hentze MW, Kulozik AE (2009) The hierarchy of exon-junction complex  
689 assembly by the spliceosome explains key features of mammalian nonsense-mediated mRNA decay.  
690 *PLoS Biol* 7: e1000120

691 Gerbracht JV, Gehring NH (2018) The exon junction complex: structural insights into a faithful  
692 companion of mammalian mRNPs. *Biochem Soc Trans* 46: 153-161

693 Gu Z, Eils R, Schlesner M (2016) Complex heatmaps reveal patterns and correlations in  
694 multidimensional genomic data. *Bioinformatics* 32: 2847-9

695 Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M,  
696 Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat  
697 J (2015) High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.  
698 *Cell* 163: 1515-26

699 Hart T, Tong AHY, Chan K, Van Leeuwen J, Seetharaman A, Aregger M, Chandrashekhar M, Hustedt N,  
700 Seth S, Noonan A, Habsid A, Sizova O, Nedyalkova L, Climie R, Tworzyanski L, Lawson K, Sartori MA,  
701 Alibeh S, Tieu D, Masud S et al. (2017) Evaluation and Design of Genome-Wide CRISPR/SpCas9  
702 Knockout Screens. *G3 (Bethesda)* 7: 2719-2727

703 Hentze MW, Castello A, Schwarzl T, Preiss T (2018) A brave new world of RNA-binding proteins. *Nat  
704 Rev Mol Cell Biol* 19: 327-341

705 Hoek TA, Khuperkar D, Lindeboom RGH, Sonneveld S, Verhagen BMP, Boersma S, Vermeulen M,  
706 Tanenbaum ME (2019) Single-Molecule Imaging Uncovers Rules Governing Nonsense-Mediated mRNA  
707 Decay. *Mol Cell* 75: 324-339 e11

708 Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke  
709 T, Gottardo R, Hahne F, Hansen KD, Irizarry RA, Lawrence M, Love MI, MacDonald J, Obenchain V, Oles  
710 AK, Pages H et al. (2015) Orchestrating high-throughput genomic analysis with Bioconductor. *Nat  
711 Methods* 12: 115-21

712 Hughes CS, Foehr S, Garfield DA, Furlong EE, Steinmetz LM, Krijgsveld J (2014) Ultrasensitive proteome  
713 analysis using paramagnetic bead technology. *Mol Syst Biol* 10: 757

714 Huntzinger E, Kashima I, Fauser M, Sauliere J, Izaurralde E (2008) SMG6 is the catalytic endonuclease  
715 that cleaves mRNAs containing nonsense codons in metazoan. *RNA* 14: 2609-17

716 Hurt JA, Robertson AD, Burge CB (2013) Global analyses of UPF1 binding and function reveal expanded  
717 scope of nonsense-mediated mRNA decay. *Genome Res* 23: 1636-50

718 Ignatiadis N, Klaus B, Zaugg JB, Huber W (2016) Data-driven hypothesis weighting increases detection  
719 power in genome-scale multiple testing. *Nat Methods* 13: 577-80

720 Ishigaki Y, Li X, Serin G, Maquat LE (2001) Evidence for a pioneer round of mRNA translation: mRNAs  
721 subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. *Cell* 106:  
722 607-17

723 Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R, Hoshino S, Ohno M, Dreyfuss G, Ohno S (2006)  
724 Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1  
725 phosphorylation and nonsense-mediated mRNA decay. *Genes Dev* 20: 355-67

726 Kataoka N, Yong J, Kim VN, Velazquez F, Perkinson RA, Wang F, Dreyfuss G (2000) Pre-mRNA splicing  
727 imprints mRNA in the nucleus with a novel RNA-binding protein that persists in the cytoplasm. *Mol Cell*  
728 6: 673-82

729 Kolesnikov N, Hastings E, Keays M, Melnichuk O, Tang YA, Williams E, Dylag M, Kurbatova N, Brandizi  
730 M, Burdett T, Megy K, Pilicheva E, Rustici G, Tikhonov A, Parkinson H, Petryszak R, Sarkans U, Brazma  
731 A (2015) ArrayExpress update--simplifying data submissions. *Nucleic Acids Res* 43: D1113-6

732 Kowarz E, Loscher D, Marschalek R (2015) Optimized Sleeping Beauty transposons rapidly generate  
733 stable transgenic cell lines. *Biotechnol J* 10: 647-53

734 Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9: 357-9

735 Lareau LF, Inada M, Green RE, Wengrod JC, Brenner SE (2007) Unproductive splicing of SR genes  
736 associated with highly conserved and ultraconserved DNA elements. *Nature* 446: 926-9

737 Larsson J (2019) eulerr: Area-Proportional Euler and Venn Diagrams with Ellipses. R package version  
738 6.0.0, <https://cran.r-project.org/package=eulerr>

739 Le Hir H, Gatfield D, Braun IC, Forler D, Izaurrealde E (2001) The protein Mago provides a link between  
740 splicing and mRNA localization. *EMBO Rep* 2: 1119-24

741 Le Hir H, Sauliere J, Wang Z (2016) The exon junction complex as a node of post-transcriptional  
742 networks. *Nat Rev Mol Cell Biol* 17: 41-54

743 Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H (2014) UpSet: Visualization of Intersecting Sets.  
744 *IEEE Trans Vis Comput Graph* 20: 1983-92

745 Li YI, Knowles DA, Humphrey J, Barbeira AN, Dickinson SP, Im HK, Pritchard JK (2018) Annotation-free  
746 quantification of RNA splicing using LeafCutter. *Nat Genet* 50: 151-158

747 Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient general purpose program for assigning  
748 sequence reads to genomic features. *Bioinformatics* 30: 923-30

749 Loh B, Jonas S, Izaurrealde E (2013) The SMG5-SMG7 heterodimer directly recruits the CCR4-NOT  
750 deadenylase complex to mRNAs containing nonsense codons via interaction with POP2. *Genes Dev* 27:  
751 2125-38

752 Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq  
753 data with DESeq2. *Genome Biol* 15: 550

754 Lykke-Andersen S, Chen Y, Ardal BR, Lilje B, Waage J, Sandelin A, Jensen TH (2014) Human nonsense-  
755 mediated RNA decay initiates widely by endonucleolysis and targets snoRNA host genes. *Genes Dev*  
756 28: 2498-517

757 Mabin JW, Woodward LA, Patton RD, Yi Z, Jia M, Wysocki VH, Bundschuh R, Singh G (2018) The Exon  
758 Junction Complex Undergoes a Compositional Switch that Alters mRNP Structure and Nonsense-  
759 Mediated mRNA Decay Activity. *Cell Rep* 25: 2431-2446 e7

760 Mansour FH, Pestov DG (2013) Separation of long RNA by agarose-formaldehyde gel electrophoresis.  
761 *Analytical biochemistry* 441: 18-20

762 Mao H, Brown HE, Silver DL (2017) Mouse models of Casc3 reveal developmental functions distinct  
763 from other components of the exon junction complex. *RNA* 23: 23-31

764 Maquat LE, Tarn WY, Isken O (2010) The pioneer round of translation: features and functions. *Cell* 142:  
765 368-74

766 Mates L, Chuah MK, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A, Grzela DP, Schmitt A, Becker K,  
767 Matrai J, Ma L, Samara-Kuko E, Gysemans C, Pryputniewicz D, Miskey C, Fletcher B, VandenDriessche  
768 T, Ivics Z, Izsvak Z (2009) Molecular evolution of a novel hyperactive Sleeping Beauty transposase  
769 enables robust stable gene transfer in vertebrates. *Nat Genet* 41: 753-61

770 Metze S, Herzog VA, Ruepp MD, Muhlemann O (2013) Comparison of EJC-enhanced and EJC-  
771 independent NMD in human cells reveals two partially redundant degradation pathways. *RNA* 19:  
772 1432-48

773 Nagy E, Maquat LE (1998) A rule for termination-codon position within intron-containing genes: when  
774 nonsense affects RNA abundance. *Trends Biochem Sci* 23: 198-9

775 Nasif S, Contu L, Muhlemann O (2018) Beyond quality control: The role of nonsense-mediated mRNA  
776 decay (NMD) in regulating gene expression. *Semin Cell Dev Biol* 75: 78-87

777 Ni JZ, Grate L, Donohue JP, Preston C, Nobida N, O'Brien G, Shiue L, Clark TA, Blume JE, Ares M, Jr.  
778 (2007) Ultraconserved elements are associated with homeostatic control of splicing regulators by  
779 alternative splicing and nonsense-mediated decay. *Genes Dev* 21: 708-18

780 Nolte H, MacVicar TD, Tellkamp F, Kruger M (2018) Instant Clue: A Software Suite for Interactive Data  
781 Visualization and Analysis. *Sci Rep* 8: 12648

782 Palacios IM, Gatfield D, St Johnston D, Izaurrealde E (2004) An eIF4AIII-containing complex required for  
783 mRNA localization and nonsense-mediated mRNA decay. *Nature* 427: 753-7

784 Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C (2017) Salmon provides fast and bias-aware  
785 quantification of transcript expression. *Nat Methods* 14: 417-419

786 Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, Inuganti A, Griss J,  
787 Mayer G, Eisenacher M, Perez E, Uszkoreit J, Pfeuffer J, Sachsenberg T, Yilmaz S, Tiwary S, Cox J, Audain  
788 E, Walzer M, Jarnuczak AF et al. (2019) The PRIDE database and related tools and resources in 2019:  
789 improving support for quantification data. *Nucleic Acids Res* 47: D442-D450

790 Perez-Silva JG, Araujo-Voces M, Quesada V (2018) nVenn: generalized, quasi-proportional Venn and  
791 Euler diagrams. *Bioinformatics* 34: 2322-2324

792 Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential  
793 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 43: e47

794 Robinson MD, Oshlack A (2010) A scaling normalization method for differential expression analysis of  
795 RNA-seq data. *Genome Biol* 11: R25

796 Rufener SC, Muhlemann O (2013) eIF4E-bound mRNPs are substrates for nonsense-mediated mRNA  
797 decay in mammalian cells. *Nat Struct Mol Biol* 20: 710-7

798 Schmidt SA, Foley PL, Jeong DH, Rymarquis LA, Doyle F, Tenenbaum SA, Belasco JG, Green PJ (2015)  
799 Identification of SMG6 cleavage sites and a preferred RNA cleavage motif by global analysis of  
800 endogenous NMD targets in human cells. *Nucleic Acids Res* 43: 309-23

801 Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. *Nature  
802 protocols* 3: 1101-8

803 Shibuya T, Tange TO, Sonenberg N, Moore MJ (2004) eIF4AIII binds spliced mRNA in the exon junction  
804 complex and is essential for nonsense-mediated decay. *Nat Struct Mol Biol* 11: 346-51

805 Singh G, Kucukural A, Cenik C, Leszyk JD, Shaffer SA, Weng Z, Moore MJ (2012) The cellular EJC  
806 interactome reveals higher-order mRNP structure and an EJC-SR protein nexus. *Cell* 151: 750-764

807 Soneson C, Love MI, Robinson MD (2015) Differential analyses for RNA-seq: transcript-level estimates  
808 improve gene-level inferences. *F1000Res* 4: 1521

809 Steckelberg AL, Altmueller J, Dieterich C, Gehring NH (2015) CWC22-dependent pre-mRNA splicing and  
810 eIF4A3 binding enables global deposition of exon junction complexes. *Nucleic Acids Res* 43: 4687-700

811 Steckelberg AL, Boehm V, Gromadzka AM, Gehring NH (2012) CWC22 connects pre-mRNA splicing and  
812 exon junction complex assembly. *Cell Rep* 2: 454-61

813 Steckelberg AL, Gehring NH (2014) Studying the composition of mRNPs in vitro using splicing-  
814 competent cell extracts. *Methods* 65: 342-9

815 Sureau A, Gattoni R, Dooghe Y, Stevenin J, Soret J (2001) SC35 autoregulates its expression by  
816 promoting splicing events that destabilize its mRNAs. *EMBO J* 20: 1785-96

817 Tani H, Imamachi N, Salam KA, Mizutani R, Ijiri K, Irie T, Yada T, Suzuki Y, Akimitsu N (2012)  
818 Identification of hundreds of novel UPF1 target transcripts by direct determination of whole  
819 transcriptome stability. *RNA Biol* 9: 1370-9

820 Thermann R, Neu-Yilik G, Deters A, Frede U, Wehr K, Hagemeier C, Hentze MW, Kulozik AE (1998)  
821 Binary specification of nonsense codons by splicing and cytoplasmic translation. *EMBO J* 17: 3484-94

822 Trcek T, Sato H, Singer RH, Maquat LE (2013) Temporal and spatial characterization of nonsense-  
823 mediated mRNA decay. *Genes Dev* 27: 541-51

824 Tuladhar R, Yeu Y, Tyler Piazza J, Tan Z, Rene Clemenceau J, Wu X, Barrett Q, Herbert J, Mathews DH,  
825 Kim J, Hyun Hwang T, Lum L (2019) CRISPR-Cas9-based mutagenesis frequently provokes on-target  
826 mRNA misregulation. *Nat Commun* 10: 4056

827 Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J (2016) The Perseus  
828 computational platform for comprehensive analysis of (prote)omics data. *Nat Methods* 13: 731-40

829 Vitting-Seerup K, Porse BT, Sandelin A, Waage J (2014) spliceR: an R package for classification of  
830 alternative splicing and prediction of coding potential from RNA-seq data. *BMC Bioinformatics* 15: 81

831 Vitting-Seerup K, Sandelin A (2017) The Landscape of Isoform Switches in Human Cancers. *Mol Cancer*  
832 *Res* 15: 1206-1220

833 Vitting-Seerup K, Sandelin A (2019) IsoformSwitchAnalyzeR: Analysis of changes in genome-wide  
834 patterns of alternative splicing and its functional consequences. *Bioinformatics*

835 Voigt F, Gerbracht JV, Boehm V, Horvathova I, Eglinger J, Chao JA, Gehring NH (2019) Detection and  
836 quantification of RNA decay intermediates using XRN1-resistant reporter transcripts. *Nature protocols*  
837 14: 1603-1633


838 Wang Z, Murigneux V, Le Hir H (2014) Transcriptome-wide modulation of splicing by the exon junction  
839 complex. *Genome Biol* 15: 551

840 Weischenfeldt J, Waage J, Tian G, Zhao J, Damgaard I, Jakobsen JS, Kristiansen K, Krogh A, Wang J,  
841 Porse BT (2012) Mammalian tissues defective in nonsense-mediated mRNA decay display highly  
842 aberrant splicing patterns. *Genome Biol* 13: R35

843 Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA, Smith CW (2004) Autoregulation of  
844 polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. *Mol*  
845 *Cell* 13: 91-100

846 Woodward LA, Mabin JW, Gangras P, Singh G (2017) The exon junction complex: a lifelong guardian of  
847 mRNA fate. *Wiley Interdiscip Rev RNA* 8

848 Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, Billis K, Cummins C, Gall A, Giron CG,  
849 Gil L, Gordon L, Haggerty L, Haskell E, Hourlier T, Izuogu OG, Janacek SH, Juettemann T, To JK, Laird MR  
850 et al. (2018) Ensembl 2018. *Nucleic Acids Res* 46: D754-D761




**Figure 1 - CASC3 is not involved in the splicing regulation of known EJC-dependent targets.**

**A-C:** RT-PCR- and quantitative RT-PCR-based detection (qPCR) of transcript isoforms of the genes RER1 (A), OCIAD1 (B), and MRPL3 (C) after siRNA-mediated knockdown of the indicated EJC components or Luciferase (Luc) as a negative control. Skipped exons are depicted schematically (e: exon). Data points and means from the qPCRs are plotted (n=3).

**D:** Relative quantification of the SRSF2 transcript isoforms by qPCR following knockdown of the indicated EJC components or Luciferase (Luc) as a negative control. The transcript variants at the position of the included exon are depicted schematically. Data points and means are plotted (n=3).

**E:** Confirmation of the knockdowns shown in A-D by western blotting.



**Figure 2 - Cells that lack CASC3 have intact EJCs and are splicing competent.**

**A:** Total protein lysates from wild-type cells (WT) and CASC3 knockout (KO) cell lines H, F and T were separated by SDS-PAGE and CASC3 was detected by western blotting. The red arrow indicates an additional band detected in the cell lines H and F and which is not visible in the WT condition or in the cell line T.

**B:** Schematic depiction of the insertions resulting in a CASC3 KO or constitutive knockdown in the indicated clones.


**C:** Total protein lysates from WT and CASC3 KO cell lines H and T were separated by SDS-PAGE and CASC3 was detected by western blotting. In lanes 3 and 5 the cells have additionally been treated with siRNAs targeting CASC3.

**D-F:** Volcano plots of mass spectrometry-based analysis of the interaction partners of EIF4A3 in WT cells and in the CASC3 KO cell line H treated with siRNAs targeting CASC3. D: EIF4A3 against FLAG control in WT cells. E: EIF4A3 against FLAG control in KO cells. F: EIF4A3 in KO cells against EIF4A3 in WT cells. The color labeling indicates targets that are significant in the respective comparisons after one-sample t-testing.

**G:** RT-PCR of transcript isoforms of the gene RER1 after siRNA-mediated knockdown of the indicated EJC components or Luciferase (Luc) as a negative control, compared to CASC3 KO cell lines H, F and T.

**H:** Relative quantification of the RER1 transcript isoforms by qPCR in WT cells treated with Luc siRNA as a negative control, CASC3 KO cell line H treated with Luc siRNA, CASC3 KO cell line H treated with CASC3 siRNAs and WT cells treated with EIF4A3 siRNA. Data points and means are plotted (n=3).

**I:** *In vitro* splicing assay of a MINX transcript in cell lysates obtained from WT cells or the CASC3 KO cell line H which stably expressed FLAG-GFP or FLAG-EIF4A3. The protein levels of CASC3 and the recombinant proteins in the cell lysates were analyzed by western blotting. The pulldown efficiencies of spliced mRNA were calculated and are plotted as individual data points and means (n=2).



**Figure 3 - CASC3-dependent targets are also affected by a perturbation of the NMD machinery.**


A: Pipeline for RNA-sequencing analysis.

B: Overlap of up- and downregulated genes in the CASC3 KO cell lines H and T, +/- CASC3 siRNAs. DGE: Differential gene expression. Due to the visualization as Euler plot, some intersections cannot be plotted. All intersections are shown in Supplementary Figure 3C.

C: Volcano plot of differential gene expression analysis of the condition H-KD using overlap from B as color and point size definition. Gene symbols are indicated for the top 25 upregulated genes detected in all four conditions and for CASC3 (colored in light red). Labels of small RNA host genes are colored in light blue. Log2 fold change is plotted against  $-\log_{10}$  padjust (adjusted p-value).

D: Matching of the top 100 upregulated genes sorted by padjust (adjusted p-value) in condition H-KD with small RNA (sRNA) host genes and comparison to knockdowns of UPF1, SMG6/7 and RNPS1.

E: Heatmap of all identified alternatively spliced junctions in the respective condition, measured in delta percent spliced in (dPSI).



**Figure 4 - Knockout of CASC3 leads to a global upregulation of NMD-sensitive transcript isoforms.**


**A:** Results from IsoformSwitch analysis plotted as volcano plots. Transcript isoforms identified as NMD-sensitive are shown as blue dots. Isoforms with no annotated open reading frame are designated as "NA". Difference in Isoform Fraction (dIF) is plotted against  $-\log_{10}$  padjust (adjusted p-value).

**B:** Quantification of transcript isoforms from SRSF2 by IsoformSwitchAnalyzeR.

**C-E:** Relative quantification of the schematically depicted transcript isoforms of the genes CLN6 (C), EMC9 (D), and SAT1 (E) by qPCR in WT cells, CASC3 KO cell lines H and T and WT cells treated with siRNA targeting UPF1. PTC: premature termination codon. Individual data points and means are plotted (n=3).

**F:** Boxplot of PTC-containing vs. non-PTC-containing transcript isoforms after IsoformSwitch analysis for all CASC3 KO conditions compared to UPF1, SMG6/7 and RNPS1. A Kolmogorov-Smirnov test was applied (p-value < 0.001 \*\*\*, p-value < 10-16 \*\*\*\*).

**G:** Euler plot showing overlaps of DTU-affected genes in the CASC3 (> 2 overlaps), UPF1-KD and SMG6/7-KD condition.



**Figure 5 - SMG6-mediated endocleavage is impaired when CASC3 is not present.**

**A:** Schematic depiction of the globin mRNA reporter. The reporter consists of three exons (orange boxes) followed by an XRN1-resistant element (xrRNA) and a probe binding cassette (gray boxes). The PTC reporter contains a premature termination codon (PTC) in the second exon.

**B:** Northern blot of RNA extracted from the indicated cell lines that stably express the globin reporter. The xrFrag corresponds to the 3' part of the reporter that is resistant to degradation by XRN1 due to the xrRNA. The cell lines in lane 3 and 6 were additionally treated with XRN1 siRNA which results in the appearance of a 3' degradation fragment below the full-length reporter. Reporter and 3' fragment mRNA levels were normalized to 7SL RNA which is shown as a loading control. For the relative mRNA quantification, in each condition (WT vs. CASC3 KO with KD) the reporter and 3' fragment levels were normalized to the globin WT reporter (lanes 1 and 4). Individual data points and means are plotted from n=3 experiments.


**C:** Schematic depiction of the TOE1 minigene reporter consisting of exons 6-8 (purple boxes) followed by a probe binding cassette (gray boxes). The reporter can be spliced to either contain the canonical stop codon (bottom right) or, by usage of an alternative 3' splice site, a PTC in exon 7 (top right).


**D:** Northern blot of RNA extracted from the indicated cell lines treated with the indicated siRNAs stably expressing the TOE1 minigene reporter. The 3' fragment levels were first normalized to the 7SL RNA loading control and for every cell line the XRN1 knockdown condition to the condition without XRN1 knockdown (n=2).

**E:** Schematic depiction of the triose phosphate isomerase (TPI) mRNA reporter. The reporter consists of seven exons (blue boxes) followed by an XRN1-resistant element (xrRNA) and a probe binding cassette (gray boxes). The PTC reporter contains a premature termination codon (PTC) in the fifth exon.

**F:** Northern blot of RNA extracted from the indicated cell lines treated with the indicated siRNAs stably expressing the either the TPI WT or TPI PTC mRNA reporter. The reporter and 3' fragment mRNA levels were normalized to the 7SL control. For each cell line, the mRNA levels were then normalized to the respective TPI WT reporter or 3' fragment levels. Individual data points and means are plotted from n=3 experiments.

**G:** Western blot of samples shown in Figure 5F.





**Figure 7 - Model of CASC3's cellular function.**

Schematic depiction of the proposed function of CASC3 in the cell. We have found no evidence that CASC3 is necessary for EJC assembly in the nucleus, although CASC3 shuttles between cytoplasm and nucleus. Transcripts that require the deposition of the EJC to be correctly spliced were not affected by a lack of CASC3. In the cytoplasm, premature termination codon (PTC)-containing transcripts may still be degraded by NMD during the initial round(s) of translation in a CASC3-independent manner. CASC3 association with the EJC maintains and/or promotes the NMD-stimulating effect of the EJC, resulting in the degradation of transcripts that evaded initial NMD activation.